PortalPublikationenHigh-risk additional chromosomal abnormalities at low blast ...

High-risk additional chromosomal abnormalities at low blast counts herald death by CML

Standard

High-risk additional chromosomal abnormalities at low blast counts herald death by CML. / Hehlmann, Rüdiger; Voskanyan, Astghik; Lauseker, Michael; Pfirrmann, Markus; Kalmanti, Lida; Rinaldetti, Sebastien; Kohlbrenner, Katharina; Haferlach, Claudia; Schlegelberger, Brigitte; Fabarius, Alice; Seifarth, Wolfgang; Spieß, Birgit; Wuchter, Patrick; Krause, Stefan; Kolb, Hans-Jochem; Neubauer, Andreas; Hossfeld, Dieter K; Nerl, Christoph; Gratwohl, Alois; Baerlocher, Gabriela M; Burchert, Andreas; Brümmendorf, Tim H; Hasford, Jörg; Hochhaus, Andreas; Saußele, Susanne; Baccarani, Michele; SAKK and the German CML Study Group.

in: LEUKEMIA, Jahrgang 34, Nr. 8, 08.2020, S. 2074-2086.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Hehlmann, R, Voskanyan, A, Lauseker, M, Pfirrmann, M, Kalmanti, L, Rinaldetti, S, Kohlbrenner, K, Haferlach, C, Schlegelberger, B, Fabarius, A, Seifarth, W, Spieß, B, Wuchter, P, Krause, S, Kolb, H-J, Neubauer, A, Hossfeld, DK, Nerl, C, Gratwohl, A, Baerlocher, GM, Burchert, A, Brümmendorf, TH, Hasford, J, Hochhaus, A, Saußele, S, Baccarani, M & SAKK and the German CML Study Group 2020, 'High-risk additional chromosomal abnormalities at low blast counts herald death by CML', LEUKEMIA, Jg. 34, Nr. 8, S. 2074-2086. https://doi.org/10.1038/s41375-020-0826-9

APA

Hehlmann, R., Voskanyan, A., Lauseker, M., Pfirrmann, M., Kalmanti, L., Rinaldetti, S., Kohlbrenner, K., Haferlach, C., Schlegelberger, B., Fabarius, A., Seifarth, W., Spieß, B., Wuchter, P., Krause, S., Kolb, H-J., Neubauer, A., Hossfeld, D. K., Nerl, C., Gratwohl, A., ... SAKK and the German CML Study Group (2020). High-risk additional chromosomal abnormalities at low blast counts herald death by CML. LEUKEMIA, 34(8), 2074-2086. https://doi.org/10.1038/s41375-020-0826-9

Vancouver

Hehlmann R, Voskanyan A, Lauseker M, Pfirrmann M, Kalmanti L, Rinaldetti S et al. High-risk additional chromosomal abnormalities at low blast counts herald death by CML. LEUKEMIA. 2020 Aug;34(8):2074-2086. https://doi.org/10.1038/s41375-020-0826-9

Bibtex

@article{95d47e143cfb489084b3a271e93bddbe,
title = "High-risk additional chromosomal abnormalities at low blast counts herald death by CML",
abstract = "Blast crisis is one of the remaining challenges in chronic myeloid leukemia (CML). Whether additional chromosomal abnormalities (ACAs) enable an earlier recognition of imminent blastic proliferation and a timelier change of treatment is unknown. One thousand five hundred and ten imatinib-treated patients with Philadelphia-chromosome-positive (Ph+) CML randomized in CML-study IV were analyzed for ACA/Ph+ and blast increase. By impact on survival, ACAs were grouped into high risk (+8, +Ph, i(17q), +17, +19, +21, 3q26.2, 11q23, -7/7q abnormalities; complex) and low risk (all other). The presence of high- and low-risk ACAs was linked to six cohorts with different blast levels (1%, 5%, 10%, 15%, 20%, and 30%) in a Cox model. One hundred and twenty-three patients displayed ACA/Ph+ (8.1%), 91 were high risk. At low blast levels (1-15%), high-risk ACA showed an increased hazard to die compared to no ACA (ratios: 3.65 in blood; 6.12 in marrow) in contrast to low-risk ACA. No effect was observed at blast levels of 20-30%. Sixty-three patients with high-risk ACA (69%) died (n = 37) or were alive after progression or progression-related transplantation (n = 26). High-risk ACA at low blast counts identify end-phase CML earlier than current diagnostic systems. Mortality was lower with earlier treatment. Cytogenetic monitoring is indicated when signs of progression surface or response to therapy is unsatisfactory.",
keywords = "Adolescent, Adult, Aged, Aged, 80 and over, Blast Crisis/genetics, Cause of Death, Chromosome Aberrations, Female, Humans, Leukemia, Myelogenous, Chronic, BCR-ABL Positive/mortality, Male, Middle Aged, Risk, Young Adult",
author = "R{\"u}diger Hehlmann and Astghik Voskanyan and Michael Lauseker and Markus Pfirrmann and Lida Kalmanti and Sebastien Rinaldetti and Katharina Kohlbrenner and Claudia Haferlach and Brigitte Schlegelberger and Alice Fabarius and Wolfgang Seifarth and Birgit Spie{\ss} and Patrick Wuchter and Stefan Krause and Hans-Jochem Kolb and Andreas Neubauer and Hossfeld, {Dieter K} and Christoph Nerl and Alois Gratwohl and Baerlocher, {Gabriela M} and Andreas Burchert and Br{\"u}mmendorf, {Tim H} and J{\"o}rg Hasford and Andreas Hochhaus and Susanne Sau{\ss}ele and Michele Baccarani and {SAKK and the German CML Study Group}",
year = "2020",
month = aug,
doi = "10.1038/s41375-020-0826-9",
language = "English",
volume = "34",
pages = "2074--2086",
journal = "LEUKEMIA",
issn = "0887-6924",
publisher = "NATURE PUBLISHING GROUP",
number = "8",

}

RIS

TY - JOUR

T1 - High-risk additional chromosomal abnormalities at low blast counts herald death by CML

AU - Hehlmann, Rüdiger

AU - Voskanyan, Astghik

AU - Lauseker, Michael

AU - Pfirrmann, Markus

AU - Kalmanti, Lida

AU - Rinaldetti, Sebastien

AU - Kohlbrenner, Katharina

AU - Haferlach, Claudia

AU - Schlegelberger, Brigitte

AU - Fabarius, Alice

AU - Seifarth, Wolfgang

AU - Spieß, Birgit

AU - Wuchter, Patrick

AU - Krause, Stefan

AU - Kolb, Hans-Jochem

AU - Neubauer, Andreas

AU - Hossfeld, Dieter K

AU - Nerl, Christoph

AU - Gratwohl, Alois

AU - Baerlocher, Gabriela M

AU - Burchert, Andreas

AU - Brümmendorf, Tim H

AU - Hasford, Jörg

AU - Hochhaus, Andreas

AU - Saußele, Susanne

AU - Baccarani, Michele

AU - SAKK and the German CML Study Group

PY - 2020/8

Y1 - 2020/8

N2 - Blast crisis is one of the remaining challenges in chronic myeloid leukemia (CML). Whether additional chromosomal abnormalities (ACAs) enable an earlier recognition of imminent blastic proliferation and a timelier change of treatment is unknown. One thousand five hundred and ten imatinib-treated patients with Philadelphia-chromosome-positive (Ph+) CML randomized in CML-study IV were analyzed for ACA/Ph+ and blast increase. By impact on survival, ACAs were grouped into high risk (+8, +Ph, i(17q), +17, +19, +21, 3q26.2, 11q23, -7/7q abnormalities; complex) and low risk (all other). The presence of high- and low-risk ACAs was linked to six cohorts with different blast levels (1%, 5%, 10%, 15%, 20%, and 30%) in a Cox model. One hundred and twenty-three patients displayed ACA/Ph+ (8.1%), 91 were high risk. At low blast levels (1-15%), high-risk ACA showed an increased hazard to die compared to no ACA (ratios: 3.65 in blood; 6.12 in marrow) in contrast to low-risk ACA. No effect was observed at blast levels of 20-30%. Sixty-three patients with high-risk ACA (69%) died (n = 37) or were alive after progression or progression-related transplantation (n = 26). High-risk ACA at low blast counts identify end-phase CML earlier than current diagnostic systems. Mortality was lower with earlier treatment. Cytogenetic monitoring is indicated when signs of progression surface or response to therapy is unsatisfactory.

AB - Blast crisis is one of the remaining challenges in chronic myeloid leukemia (CML). Whether additional chromosomal abnormalities (ACAs) enable an earlier recognition of imminent blastic proliferation and a timelier change of treatment is unknown. One thousand five hundred and ten imatinib-treated patients with Philadelphia-chromosome-positive (Ph+) CML randomized in CML-study IV were analyzed for ACA/Ph+ and blast increase. By impact on survival, ACAs were grouped into high risk (+8, +Ph, i(17q), +17, +19, +21, 3q26.2, 11q23, -7/7q abnormalities; complex) and low risk (all other). The presence of high- and low-risk ACAs was linked to six cohorts with different blast levels (1%, 5%, 10%, 15%, 20%, and 30%) in a Cox model. One hundred and twenty-three patients displayed ACA/Ph+ (8.1%), 91 were high risk. At low blast levels (1-15%), high-risk ACA showed an increased hazard to die compared to no ACA (ratios: 3.65 in blood; 6.12 in marrow) in contrast to low-risk ACA. No effect was observed at blast levels of 20-30%. Sixty-three patients with high-risk ACA (69%) died (n = 37) or were alive after progression or progression-related transplantation (n = 26). High-risk ACA at low blast counts identify end-phase CML earlier than current diagnostic systems. Mortality was lower with earlier treatment. Cytogenetic monitoring is indicated when signs of progression surface or response to therapy is unsatisfactory.

KW - Adolescent

KW - Adult

KW - Aged

KW - Aged, 80 and over

KW - Blast Crisis/genetics

KW - Cause of Death

KW - Chromosome Aberrations

KW - Female

KW - Humans

KW - Leukemia, Myelogenous, Chronic, BCR-ABL Positive/mortality

KW - Male

KW - Middle Aged

KW - Risk

KW - Young Adult

U2 - 10.1038/s41375-020-0826-9

DO - 10.1038/s41375-020-0826-9

M3 - SCORING: Journal article

C2 - 32382082

VL - 34

SP - 2074

EP - 2086

JO - LEUKEMIA

JF - LEUKEMIA

SN - 0887-6924

IS - 8

ER -